Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.56 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30530079 | 0.92 | SCN8A (0.67) | SCN8ASCN10A | |
| SCHEMBL25373379 | 0.92 | SCN8A (0.67) | SCN8ASCN10A | |
| SCHEMBL13852936 | 0.91 | SCN8A (0.56) | SCN8ASCN10A | |
| SCHEMBL14372450 | 0.85 | — | — | |
| SCHEMBL20644021 | 0.85 | SCN8A (0.66) | SCN8ASCN10A | |
| SCHEMBL13852935 | 0.84 | SCN8A (0.55) | SCN8ASCN10A | |
| SCHEMBL3662620 | 0.84 | SCN8A (0.55) | SCN8ASCN10A | |
| SCHEMBL30530118 | 0.82 | SCN10A (0.67) | SCN8ASCN10A | |
| SCHEMBL29062028 | 0.82 | SCN10A (0.67) | SCN8ASCN10A | |
| SCHEMBL14372467 | 0.82 | SCN8A (0.53) | SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779197-B2 | Aryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779197-B2 | Aryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118338-A1 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | KCNH2, KCNH3, SCN5A | SCN8A 63/4885SCN10A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.